These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 30514791)

  • 1. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
    Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
    Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
    Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
    Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
    Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
    Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy.
    Satoh Y; Kotani H; Iida Y; Taniura T; Notsu Y; Harada M
    Cancer Sci; 2020 Jul; 111(7):2248-2258. PubMed ID: 32426941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
    Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD
    Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD205
    Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
    Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
    Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.